Open an account

Bicycle Therapeutics

BCYC · NASDAQ

$3.60+$0.065 (+1.84%)TodayMarket closed ·
Prev close $3.54

About BCYC

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 288 full-time employees. The company went IPO on 2019-05-23. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The firm is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.

Employees
288
Headquarters
Cambridge, Cambridgeshire
Listed
May 23, 2019
Sector
Health Care
Industry
Biotechnology
Website
bicycletherapeutics.com

BCYC key statistics

Market cap
246.79M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
512.31K
Volume
488.22K
Open price
$3.53
High today
$3.71
Low today
$3.52
52 Week high
$9.08
52 Week low
$3.33

Bicycle Therapeutics (BCYC) at a glance

Bicycle Therapeutics (BCYC) last traded at $3.60, with a market cap of 246.79M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.52 and $3.71. The current price is 2.3% above the day's low and 3.0% below its high.

Volume so far is 488.22K shares, in line with the average of 512.31K shares a day.

Over the past year Bicycle Therapeutics has ranged from $3.33 to $9.08, and now sits 5% of the way up that range.

Bicycle Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.72 per share against an estimate of -$0.5871.

The average analyst price target is $10.35, 187.4% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

57%of 7 analyst ratings say Buy
  • Buy57.1%
  • Hold42.9%
  • Sell0.0%
Price target · 9 analystsAvg $10.35
Low
$5.05
Now
$3.60
High
$14.70

BCYC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 26.5% on average.

  1. Q3 FY24: reported -$0.74 per share against an estimate of -$0.7973
  2. Q4 FY24: reported -$0.82 per share against an estimate of -$0.8757
  3. Q1 FY25: reported -$0.88 per share against an estimate of -$0.8591
  4. Q2 FY25: reported -$1.14 per share against an estimate of -$0.9706
  5. Q3 FY25: reported -$0.85 per share against an estimate of -$1.10
  6. Q4 FY25: reported -$0.29 per share against an estimate of -$0.9559
  7. Q1 FY26: reported -$0.87 per share against an estimate of -$0.6333
  8. Q2 FY26: reported -$0.72 per share against an estimate of -$0.5871

BCYC news

  • Press releaseBusiness Wire

    Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting

  • Press releaseBusiness Wire

    Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting

  • Press releaseBusiness Wire

    Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026

  • Press releaseBusiness Wire

    Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026

  • Press releaseBusiness Wire

    Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

  • Press releaseBusiness Wire

    Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline

Similar companies

Companies in the same industry as Bicycle Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.